164 related articles for article (PubMed ID: 28912497)
1. Selective antibody activation through protease-activated pro-antibodies that mask binding sites with inhibitory domains.
Chen IJ; Chuang CH; Hsieh YC; Lu YC; Lin WW; Huang CC; Cheng TC; Cheng YA; Cheng KW; Wang YT; Chen FM; Cheng TL; Tzou SC
Sci Rep; 2017 Sep; 7(1):11587. PubMed ID: 28912497
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
Fischer T; Riedl R
Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
[TBL] [Abstract][Full Text] [Related]
3. Functional selection of protease inhibitory antibodies.
Lopez T; Mustafa Z; Chen C; Lee KB; Ramirez A; Benitez C; Luo X; Ji RR; Ge X
Proc Natl Acad Sci U S A; 2019 Aug; 116(33):16314-16319. PubMed ID: 31363054
[TBL] [Abstract][Full Text] [Related]
4. Identification of highly selective MMP-14 inhibitory Fabs by deep sequencing.
Lopez T; Nam DH; Kaihara E; Mustafa Z; Ge X
Biotechnol Bioeng; 2017 Jun; 114(6):1140-1150. PubMed ID: 28090632
[TBL] [Abstract][Full Text] [Related]
5. Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis.
Remacle AG; Cieplak P; Nam DH; Shiryaev SA; Ge X; Strongin AY
Oncotarget; 2017 Jan; 8(2):2781-2799. PubMed ID: 27835863
[TBL] [Abstract][Full Text] [Related]
6. In-depth biophysical analysis of interactions between therapeutic antibodies and the extracellular domain of the epidermal growth factor receptor.
Alvarenga ML; Kikhney J; Hannewald J; Metzger AU; Steffens KJ; Bomke J; Krah A; Wegener A
Anal Biochem; 2012 Feb; 421(1):138-51. PubMed ID: 22085444
[TBL] [Abstract][Full Text] [Related]
7. Role of N-glycosylation in EGFR ectodomain ligand binding.
Azimzadeh Irani M; Kannan S; Verma C
Proteins; 2017 Aug; 85(8):1529-1549. PubMed ID: 28486782
[TBL] [Abstract][Full Text] [Related]
8. Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.
Nam DH; Lee KB; Kruchowy E; Pham H; Ge X
Biochemistry; 2020 Oct; 59(40):3802-3812. PubMed ID: 32997500
[TBL] [Abstract][Full Text] [Related]
9. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
Qin W; Feng J; Li Y; Lin Z; Shen B
Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
[TBL] [Abstract][Full Text] [Related]
10. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility.
Lammerts van Bueren JJ; Bleeker WK; Brännström A; von Euler A; Jansson M; Peipp M; Schneider-Merck T; Valerius T; van de Winkel JG; Parren PW
Proc Natl Acad Sci U S A; 2008 Apr; 105(16):6109-14. PubMed ID: 18427122
[TBL] [Abstract][Full Text] [Related]
11. De novo design TNF-alpha antagonistic peptide based on the complex structure of TNF-alpha with its neutralizing monoclonal antibody Z12.
Qin W; Feng J; Li Y; Lin Z; Shen B
J Biotechnol; 2006 Aug; 125(1):57-63. PubMed ID: 16522339
[TBL] [Abstract][Full Text] [Related]
12. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
Jani M; Tordai H; Trexler M; Bányai L; Patthy L
Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
[TBL] [Abstract][Full Text] [Related]
13. Role of PKC-α in NF-κB-MT1-MMP-mediated activation of proMMP-2 by TNF-α in pulmonary artery smooth muscle cells.
Roy S; Chakraborti T; Chowdhury A; Chakraborti S
J Biochem; 2013 Mar; 153(3):289-302. PubMed ID: 23266860
[TBL] [Abstract][Full Text] [Related]
14. Generation of inhibitory monoclonal antibodies targeting matrix metalloproteinase-14 by motif grafting and CDR optimization.
Nam DH; Fang K; Rodriguez C; Lopez T; Ge X
Protein Eng Des Sel; 2017 Feb; 30(2):113-118. PubMed ID: 27986919
[TBL] [Abstract][Full Text] [Related]
15. Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.
Donaldson JM; Kari C; Fragoso RC; Rodeck U; Williams JC
Cancer Biol Ther; 2009 Nov; 8(22):2147-52. PubMed ID: 19783899
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains.
Martens E; Leyssen A; Van Aelst I; Fiten P; Piccard H; Hu J; Descamps FJ; Van den Steen PE; Proost P; Van Damme J; Liuzzi GM; Riccio P; Polverini E; Opdenakker G
Biochim Biophys Acta; 2007 Feb; 1770(2):178-86. PubMed ID: 17137715
[TBL] [Abstract][Full Text] [Related]
17. Generation of highly selective monoclonal antibodies inhibiting a recalcitrant protease using decoy designs.
Lee KB; Dunn ZS; Lopez T; Mustafa Z; Ge X
Biotechnol Bioeng; 2020 Dec; 117(12):3664-3676. PubMed ID: 32716053
[TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of matrix metalloproteinase 10 (MMP10) with a single-domain antibody.
Razai AS; Eckelman BP; Salvesen GS
J Biol Chem; 2020 Feb; 295(8):2464-2472. PubMed ID: 31953328
[TBL] [Abstract][Full Text] [Related]
19. Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries.
Nam DH; Rodriguez C; Remacle AG; Strongin AY; Ge X
Proc Natl Acad Sci U S A; 2016 Dec; 113(52):14970-14975. PubMed ID: 27965386
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
